News

Personalized Cancer Prevention Takes Center Stage During Clinical Research Week

Scheduled to begin on May 18, this year’s Gustave Roussy Clinical Research Week will focus on personalized cancer prevention and the essential role that clinical research plays in advancing it. Hosted by health journalist Odile Pouget, a dedicated webinar will be held on May 21 at 6:00 p.m., featuring experts from Gustave Roussy. 

Published on

Changed on

bandeau Semaine de la recherche clinique

Every year in May, Gustave Roussy takes the opportunity to highlight clinical research, the cornerstone of access to innovation in oncology and essential for the development of new therapies and techniques to fight cancer more effectively.

This year, the various events planned will focus on the theme of personalized cancer prevention. Entitled “Toward Tailored Cancer Prevention: How Research Is Making a Difference,” this year’s event will feature:

  • From May 18 to 24, an educational exhibition dedicated to clinical research on the Gustave Roussy outpatient floor.
  • Thursday, May 21, at 6:00 p.m.: a webinar open to the general public, featuring experts from Gustave Roussy and moderated by Odile Pouget, a health journalist.

► Watch the webinar 

Prevention and Clinical Research

It is estimated that 40% of cancer cases worldwide are linked to modifiable and identifiable risk factors[1]. To address this issue, Gustave Roussy launched the Interception program in 2021, which offers various personalized prevention pathways. The goal? To intervene early with individuals at increased risk (genetic predispositions, tobacco, alcohol, etc.) through tailored support and follow-up, to reduce the risk of developing the disease and, if it does develop, to detect it as early as possible.

With a rise in cancer incidence projected for the coming decades[2], strengthening the role and effectiveness of prevention is becoming a major public health priority. Clinical research plays a fundamental role in meeting these objectives by identifying new predictive biomarkers. These biomarkers are signatures present in the body that can help identify individuals at increased risk of developing cancer years before the disease appears. The LEAH clinical study, led by Gustave Roussy, aims to identify new predictive biomarkers through the Interception program.

Voir la vidéo Interception ► Watch the video on YouTube

Clinical Research at Gustave Roussy

Clinical research is at the heart of Gustave Roussy’s mission. In 2025, 618 studies were underway there, including 516 therapeutic trials.

 To better understand the objectives of clinical trials, the different types, how they are designed, or to understand the differences between Phase I, II, and III trials, visit the Gustave Roussy consultation area from May 18 to 24, where an educational exhibition will be held.

► For more information on cancer prevention

► For more information on clinical research

 


[1] Fink H. et al., “Global and regional cancer burden attributable to modifiable risk factors to inform prevention,” *Nature Medicine*, vol. 32, pp. 1306–1315, 2026.

[2] Force L, Kocarnik J, May M et al. The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023

The Lancet, 2025; 406, 1565–1586

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin